Antibiotics Pharmacokinetics and Efficacy Peer reviewed

Evaluation of the Achievement of a Pharmacodynamic Target of Piperacillin‐Tazobactam for the Population With Obesity: An Open Randomized Controlled Feasibility Study (TAZO‐OBESITY Trial)

Sabrina Larocque, Juliette Fournier, Justine Brasseur‐Masse, Britanny Bernard and 5 more

Fundamental and Clinical Pharmacology | Oct 21, 2026

Scollr summary

What this paper is about

This first RCT evaluating prolonged infusions of piperacillin-tazobactam in the obese population demonstrated the feasibility of the protocol and suggest a favorable trend for fT > MIC attainment and no safety signal for prolonged infusions and support the conduct of a larger scale RCT.

Full abstract

Read the full abstract

BACKGROUND: Observational studies report that prolonged infusions of piperacillin-tazobactam may enable the achievement of an optimal clinically targeted free drug concentration above the minimum inhibitory concentration (fT > MIC). OBJECTIVES: This study aimed to assess the feasibility of a randomized controlled trial (RCT) comparing standard to prolonged infusions of piperacillin-tazobactam in the obese population. METHODS: or higher who initiated piperacillin-tazobactam were recruited and randomly assigned to receive either standard or prolonged infusions of the antibiotic. Feasibility and safety outcomes were assessed. A blood sample was collected 24 h after the intervention to measure total piperacillin concentrations, with an exploratory aim of determining the proportion of patients who achieved 100% fT > MIC. RESULTS: A total of 45 patients were recruited at a rate of 7.2 patients per month with a consent rate of 42.1%, achieving these feasibility objectives. Adherence to blood sampling was 77.8%, below the 80% objective. On an exploratory basis, the proportion of patients who achieved 100% fT > MIC 24 h postintervention was 64.3% in the prolonged-infusion group and 55.6% in the standard-infusion group (p = 0.725). There was no significant difference in the safety outcomes (p = 0.756). CONCLUSION: This first RCT evaluating prolonged infusions of piperacillin-tazobactam in the obese population demonstrated the feasibility of the protocol. Although not statistically significant, the results suggest a favorable trend for fT > MIC attainment and no safety signal for prolonged infusions and support the conduct of a larger scale RCT. TRIAL REGISTRATION: Clinical trial registration: NCT #06690905.

Direct answer

What can I do from this paper page?

Use this page to scan "Evaluation of the Achievement of a Pharmacodynamic Target of Piperacillin‐Tazobactam for the Population With Obesity: An Open Randomized Controlled Feasibility Study (TAZO‐OBESITY Trial)" quickly: start with the summary and abstract, then check the authors, source, topics, and related papers. From here, open Scollr to follow Antibiotics Pharmacokinetics and Efficacy research, save the paper, or map adjacent work.

Authors

Researchers on this paper

Sabrina Larocque

first | Université de Montréal

Juliette Fournier

middle | Université de Montréal

Justine Brasseur‐Masse

middle | Université de Montréal

Britanny Bernard

middle | Université de Montréal

Guiva Annane

middle | Université de Montréal | ORCID 0009-0005-3320-0900

Louis‐Patrick Haraoui

middle | Canadian Institute for Advanced Research | ORCID 0000-0002-3713-7866

Anis Ouyahia

middle | Santé Montérégie

Amélie Marsot

middle | Centre Hospitalier Universitaire Sainte-Justine | ORCID 0000-0002-9303-8862

Benoît Crevier

last | Santé Montérégie | ORCID 0000-0002-1837-1585

Research areas

Follow related topics

Citation

BibTeX

@article{Larocque2026Evaluation,
  title = {Evaluation of the Achievement of a Pharmacodynamic Target of Piperacillin‐Tazobactam for the Population With Obesity: An Open Randomized Controlled Feasibility Study (TAZO‐OBESITY Trial)},
  author = {Sabrina Larocque and Juliette Fournier and Justine Brasseur‐Masse and Britanny Bernard and Guiva Annane and Louis‐Patrick Haraoui and Anis Ouyahia and Amélie Marsot and Benoît Crevier},
  journal = {Fundamental and Clinical Pharmacology},
  year = {2026},
  doi = {10.1111/fcp.70116},
  url = {https://doi.org/10.1111/fcp.70116}
}

FAQ

Using this paper in a discovery workflow

How do I find related work for this paper?

Use the related papers and topic links on this page as starting points. In Scollr, you can also open the paper and build a literature map around its references, citing papers, and related work.

How can I keep up with new Antibiotics Pharmacokinetics and Efficacy research papers?

Follow Antibiotics Pharmacokinetics and Efficacy research in Scollr. New papers from the topic flow into a personalized feed, and you can save useful studies to revisit later.

Can I cite this paper from this page?

This page includes a static BibTeX block for Evaluation of the Achievement of a Pharmacodynamic Target of Piperacillin‐Tazobactam for the Population With Obesity: An Open Randomized Controlled Feasibility Study (TAZO‐OBESITY Trial). Always verify the DOI, source, and publication details against the publisher record before submitting a manuscript.

Follow this research in Scollr

Follow the topics and authors behind this paper, save useful studies, and build a literature map when you are ready to go deeper.

Get the app